Aberdeen Group
EVMN

Aberdeen Group’s Evommune Inc EVMN Stock Holding History

Aberdeen Group’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-525,376
Closed -$8.99M – 975
2025
Q4 		$8.99M Buy
+525,376
New +$9.87M 0.01% 627

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Aberdeen Group's EVMN Position: Q1 2026 in Review

Aberdeen Group sold out of Evommune Inc (EVMN) in Q1 2026, closing a stake of 525,376 shares — an estimated $8.99M sold.

Aberdeen Group first reported a position in EVMN in Q4 2025 and held it in 1 quarter. The position peaked at $8.99M in Q4 2025. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • Aberdeen Group reported no remaining Evommune Inc position as of Q1 2026 after selling out during the quarter.
  • Aberdeen Group sold 525,376 Evommune Inc shares in Q1 2026, an estimated $8.99M.
  • Aberdeen Group first reported a position in Evommune Inc in Q4 2025 and held it in 1 quarter.
  • Aberdeen Group's Evommune Inc position peaked at $8.99M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.